Immunologically, UDCA degrades TGF-β to inhibit Tregs differentiation and synergizes with anti-PD-1 by augmenting tumor-specific CD8+ T cell memory, correlating with improved objective response rates in retrospective cohorts [148]. Here, TGFB1 is linked to neoplasm.